Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $.01 per share
-
Shares outstanding
-
7.01M
-
Number of holders
-
10
-
Total 13F shares, excl. options
-
646K
-
Shares change
-
+636K
-
Total reported value, excl. options
-
$3.8M
-
Value change
-
+$3.74M
-
Number of buys
-
9
-
Price
-
$5.88
Significant Holders of Traws Pharma, Inc. - Common Stock, par value $.01 per share (TRAW) as of Q3 2024
10 filings reported holding TRAW - Traws Pharma, Inc. - Common Stock, par value $.01 per share as of Q3 2024.
Traws Pharma, Inc. - Common Stock, par value $.01 per share (TRAW) has 10 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 646K shares
of 7.01M outstanding shares and own 9.22% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (606K shares), VANGUARD GROUP INC (26.7K shares), BlackRock, Inc. (9.96K shares), BANK OF AMERICA CORP /DE/ (2.14K shares), MORGAN STANLEY (729 shares), UBS Group AG (630 shares), Tower Research Capital LLC (TRC) (379 shares), Vermillion & White Wealth Management Group, LLC (205 shares), GROUP ONE TRADING LLC (64 shares), and Pacific Capital Wealth Advisors, Inc. (2 shares).
This table shows the top 10 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.